New York State Teachers Retirement System Has $6.61 Million Position in Halozyme Therapeutics, Inc. $HALO

New York State Teachers Retirement System reduced its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 0.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 126,980 shares of the biopharmaceutical company’s stock after selling 234 shares during the quarter. New York State Teachers Retirement System’s holdings in Halozyme Therapeutics were worth $6,605,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in HALO. Wealth Preservation Advisors LLC purchased a new position in shares of Halozyme Therapeutics during the 1st quarter valued at $32,000. SVB Wealth LLC purchased a new position in shares of Halozyme Therapeutics during the 1st quarter valued at $33,000. Bessemer Group Inc. grew its holdings in shares of Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 207 shares in the last quarter. Brooklyn Investment Group grew its holdings in shares of Halozyme Therapeutics by 1,558.1% during the 1st quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 670 shares in the last quarter. Finally, Park Place Capital Corp grew its holdings in shares of Halozyme Therapeutics by 20.1% during the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock valued at $69,000 after acquiring an additional 182 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Trading Up 0.2%

Shares of NASDAQ:HALO opened at $67.03 on Monday. The stock has a market capitalization of $7.84 billion, a PE ratio of 15.34, a P/E/G ratio of 0.36 and a beta of 1.16. Halozyme Therapeutics, Inc. has a 1 year low of $42.01 and a 1 year high of $79.50. The firm has a fifty day moving average price of $71.56 and a 200 day moving average price of $62.09. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.31. The firm had revenue of $325.72 million during the quarter, compared to analysts’ expectations of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. Halozyme Therapeutics’s revenue for the quarter was up 40.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $75.24, for a total transaction of $150,480.00. Following the completion of the sale, the director directly owned 44,952 shares in the company, valued at $3,382,188.48. This represents a 4.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $69.03, for a total transaction of $1,380,600.00. Following the sale, the chief executive officer owned 733,719 shares of the company’s stock, valued at $50,648,622.57. This trade represents a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 108,227 shares of company stock worth $7,779,595 over the last ninety days. Company insiders own 2.90% of the company’s stock.

Analysts Set New Price Targets

HALO has been the topic of several research analyst reports. Wall Street Zen cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, September 5th. JMP Securities boosted their price target on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the company a “market outperform” rating in a report on Wednesday, August 6th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. JPMorgan Chase & Co. boosted their price target on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. Finally, Leerink Partners upgraded shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price target on the stock in a report on Tuesday, October 14th. Five analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $73.00.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.